A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET in the Detection of Beta Amyloid in Subjects With Probable Alzheimer's Disease, Older Healthy Volunteers, and Young Healthy Volunteers

Trial Profile

A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET in the Detection of Beta Amyloid in Subjects With Probable Alzheimer's Disease, Older Healthy Volunteers, and Young Healthy Volunteers

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2016

At a glance

  • Drugs Flutafuranol F 18 (Primary)
  • Indications Alzheimer's disease
  • Focus Diagnostic use
  • Sponsors Navidea Biopharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Mar 2016 Planned End Date changed from 1 Dec 2013 to 1 Dec 2018, according to ClinicalTrials.gov record.
    • 29 Mar 2016 Planned primary completion date changed from 1 Dec 2013 to 1 Dec 2018, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top